CONGRESS ABSTRACT

Cardiac contractility modulation (CCM) is an innovative therapeutic strategy for chronic heart failure, particularly in patients with reduced or moderately impaired left ventricular ejection fraction. Unlike conventional therapies that primarily reduce hemodynamic load or modulate neurohormonal pathways, CCM directly enhances myocardial contractile function. The delivery of high-voltage biphasic electrical…

A 72-year-old female patient with non-ischemic dilated cardiomyopathy (FE 30%) presented to our attention due to persistent dyspnea, despite optimized medical therapy for heart failure. In particular, her medication regimen included: sacubitril/valsartan 49/51 x2/die, dapagliflozin 10 mg/die, bisoprolol 7.5 mg/die, furosemide 25 mg/die, and vericiguat 10 mg/die (the latter…

We present the clinical case of a 70-year-old male patient with multiple cardiovascular risk factors and no previous cardiac history. The first admission to our institution was in December 2023 for heart failure with reduced ejection fraction (LVEF 20–25%) with coronary arteries without critical stenoses and atrial fibrillation (AF)…

INTRODUCTION: In heart failure, profound cellular and molecular changes have recently been documented. Cardiac contractility modulation therapy appears to act precisely at these levels. CASE REPORT: We present the case of a 73-year-old man. In August 2016, the patient experienced an acute coronary syndrome and underwent percutaneous coronary revascularization….

A 75-year-old woman with no known cardiovascular disease was admitted for acute decompensated heart failure. She reported months of progressive exertional dyspnea. Electrocardiography revealed atrial fibrillation with rapid ventricular response (~140 bpm). Transthoracic echocardiography showed reduced left ventricular ejection fraction (LVEF 40%) with diffuse hypokinesia, severe atrial dilation with…